Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insufficient physical activity Clear all
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab SC, Placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
79
States / cities
Sun City, Arizona • Corona, California • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

NCT05971940
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
41
States / cities
Sheffield, Alabama • Surprise, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 10:29 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

NCT05419297
View directory record Official record
Conditions
Back Pain Lower Back Chronic, Chronic Pain
Interventions
Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep
Drug · Other · Device + 1 more
Lead sponsor
Carolinas Pain Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

NCT00263276
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dapagliflozin, placebo, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 79 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
111
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 4 Interventional Results available

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

NCT01864174
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 3, 2026, 10:29 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

NCT07373743
View directory record Official record
Conditions
Pharmacokinetic in Normal Population
Interventions
Tafenoquine Oral Tablet
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 3, 2026, 10:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiologic Correlates of Hypersomnia

NCT01719315
View directory record Official record
Conditions
Major Depressive Disorder, Primary Hypersomnia, Bipolar Disorder, Narcolepsy, Primary Insomnia
Interventions
Acoustical slow wave induction
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients

NCT01982994
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
Education/Daily Planning
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

NCT02008565
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Loperamide, Placebo, Anal exercises with biofeedback, Usual Care
Drug · Behavioral
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Not applicable Interventional Results available

The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS

NCT05299723
View directory record Official record
Conditions
Sleep Disturbance, Insomnia, Acute Coronary Syndrome
Interventions
BLT Intervention, BLB Intervention, Sleep Hygiene Education
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

NCT00095147
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 3, 2026, 10:29 AM EDT
Active, not recruiting Not applicable Interventional Results available

Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum

NCT03909178
View directory record Official record
Conditions
Acetabular Labrum Tear, Femoro Acetabular Impingement, Hip Arthroscopy, Physical Therapy, Osteoarthritis, Hip
Interventions
Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group), Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

NCT01111955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-823778, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hialeah, Florida • Olympia, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity

NCT04802291
View directory record Official record
Conditions
Healthy Lifestyle, Home Environment Related Disease, Cognitive Change, Child Behavior, Child Obesity, Parenting, Parents, Parent-Child Relations
Interventions
HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
24 Years to 50 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

NCT00960076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Jonesboro, Arkansas • Anaheim, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 3, 2026, 10:29 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 1 Interventional

Allogeneic Virus-specific T Cell Lines (VSTs)

NCT02510417
View directory record Official record
Conditions
Viral Infections After HSCT
Interventions
VSTs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
4 Weeks to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 3, 2026, 10:29 AM EDT
Recruiting Phase 2 Interventional

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

NCT06846320
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
49
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

NCT00683657
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Escondido, California • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Metformin, Placebo, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Concord, California • Encinitas, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 3, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

NCT07207122
View directory record Official record
Conditions
Parkinson Disease
Interventions
Gen0Bh Transcranial Focused Ultrasound System (Active), Gen0Bh Transcranial Focused Ultrasound System (Sham)
Device
Lead sponsor
Sanmai Technologies PBC dba Sanmai
Industry
Eligibility
22 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Tucson, Arizona • Santa Monica, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 10:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

NCT01177813
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 3, 2026, 10:29 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 3, 2026, 10:29 AM EDT
Recruiting Not applicable Interventional

Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

NCT06827288
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUN, SUN + Telebridge, ED-ITT, ED-ITT + BHS
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 3, 2026, 10:29 AM EDT